HC Wainwright & Co. : Reneo Pharmaceuticals (RPHM.US) rating was reaffirmed and adjusted from neutral to neutral, with a target price of $1.50.
Reneo Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Reneo Pharmaceuticals, Maintains $1.5 Price Target
Mitchell Kapoor's Hold Rating on Reneo Pharmaceuticals Amid OnKure Merger and Oncology Pipeline Potential
Maintaining Hold on Reneo Pharmaceuticals Amidst Strategic Uncertainties and Pipeline Setbacks
Sell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Target
Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC)
Leerink Partners Downgrades Reneo Pharmaceuticals to Market Perform, Announces $1 Price Target
Reneo Pharmaceuticals Analyst Ratings
Hold Rating and Lowered Price Target for Reneo Pharmaceuticals Following STRIDE Study Setback and Operational Challenges
Baird Downgrades Reneo Pharmaceuticals to Neutral From Outperform, Cuts Price Target to $3 From $28
Reneo Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Reneo Pharmaceuticals, Maintains $30 Price Target
Reneo Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Reneo Pharmaceuticals (RPHM), Astria Therapeutics (ATXS) and Scholar Rock Holding (SRRK)
HC Wainwright & Co. Reiterates Buy on Reneo Pharmaceuticals, Maintains $30 Price Target
Reneo Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Reneo Pharmaceuticals (RPHM), Pulmonx (LUNG) and Orchestra BioMed Holdings (OBIO)
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Reneo Pharmaceuticals (RPHM)
HC Wainwright & Co. Reiterates Buy on Reneo Pharmaceuticals, Maintains $30 Price Target
No Data